Gossamer Bio
GOSS
131 hedge funds and large institutions have $665M invested in Gossamer Bio in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 42 reducing their positions, and 13 closing their positions.
182% more capital inflows, than outflows
Capital inflows: $89.9M | Capital outflows: $31.9M
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
4.87% more ownership
Funds ownership: 72.05% → 76.92% (+4.9%)
5% more funds holding
Funds holding: 125 → 131 (+6)
2% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 42
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less call options, than puts
Call options by funds: $3.51M | Put options by funds: $4.98M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Woodline Partners
San Francisco,
California
|
+$11.6M |
| 2 |
Morgan Stanley
New York
|
+$11.5M |
| 3 |
OrbiMed
New York
|
+$8.11M |
| 4 |
State Street
Boston,
Massachusetts
|
+$7.47M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$6.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ally Bridge Group
New York
|
-$8.31M |
| 2 |
Goldman Sachs
New York
|
-$3.89M |
| 3 |
Millennium Management
New York
|
-$3.56M |
| 4 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$2.86M |
| 5 |
Ikarian Capital
Dallas,
Texas
|
-$2.2M |
GOSS Hedge Fund Activity: Q4 2021 in Review
131 of the 6,521 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q4 2021, worth a combined $665M — down 3.3% from $688M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new GOSS positions and 13 closed out — a net gain of 7 holders — while 41 added to existing stakes and 42 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $11.6M. The largest seller was Ally Bridge Group, cutting an estimated $8.31M.
- 131 institutional investors held Gossamer Bio (GOSS) as of Q4 2021, up from 125 in Q3 2021.
- Funds reported $665M of Gossamer Bio stock for Q4 2021, down 3.3% quarter-over-quarter.
- 20 funds opened new Gossamer Bio positions in Q4 2021 and 13 closed out, a net change of +7 holders.
- The largest Gossamer Bio buyer in Q4 2021 was Woodline Partners, an estimated $11.6M added.
- The largest Gossamer Bio seller in Q4 2021 was Ally Bridge Group, an estimated $8.31M sold.
Based on aggregated 13F filings for Q4 2021.